Windtree Therapeutics

WINT

Market cap $3.15M

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C

Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build Corp displaying the underlying demand for the coin globally WARRINGTON, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced large reductions in outstanding shares of its preferred series C and D shares.

Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit (“ELOC”) and bolster its BNB cryptocurrency treasury strategy.

Windtree expected to become a leader and the first NASDAQ-listed company offering direct exposure to the Binance Smart Chain Ecosystem (BNB) Windtree expected to become a leader and the first NASDAQ-listed company offering direct exposure to the Binance Smart Chain Ecosystem (BNB)

1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old

Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs  by over 50% by end of 2026 Tech transfer underway with validation batch manufacturing expected to begin in 2026 Evofem and Windtree exploring other partnerships WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (Nasdaq: WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem's hormone-free contraceptive product, PHEXXI ® (lactic acid, citric acid and potassium bitartrate), at a cost that is significantly below current levels.

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program

ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogenic shock If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogenic shock

-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse.